Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 17

Results For "March"

843 News Found

Bliss GVS Pharma posts Q4 FY25 consolidated PAT at Rs. 15.53 Cr
News | May 13, 2025

Bliss GVS Pharma posts Q4 FY25 consolidated PAT at Rs. 15.53 Cr

The company has posted net profit of Rs. 84.29 crores for the Financial Year ended March 31, 2025


Morepen Laboratories reports Q4 FY25 consolidated PAT at Rs. 20.31 Cr
News | May 13, 2025

Morepen Laboratories reports Q4 FY25 consolidated PAT at Rs. 20.31 Cr

The company has posted net profit of Rs. 118.01 crores for the Financial Year ended March 31, 2025


Poly Medicure posts Q4 FY25 consolidated profit at Rs. 91.83 Cr
News | May 12, 2025

Poly Medicure posts Q4 FY25 consolidated profit at Rs. 91.83 Cr

The company has posted net profit of Rs. 338.55 crores for the Financial Year ended March 31, 2025


Dabur India posts Q4 FY25 consolidated PAT at Rs. 320.13 Cr
News | May 12, 2025

Dabur India posts Q4 FY25 consolidated PAT at Rs. 320.13 Cr

The company has posted net profit of Rs. 1,767.63 crores for the Financial Year ended March 31, 2025


Jagsonpal Pharmaceuticals posts Q4 FY25 PAT at Rs. 6.58 Cr
News | May 12, 2025

Jagsonpal Pharmaceuticals posts Q4 FY25 PAT at Rs. 6.58 Cr

The company has posted net profit of Rs. 55.36 crores for the Financial Year ended March 31, 2025


Aarti Drugs Ltd Q4 FY2025 consolidated PAT climbs to Rs. 62.86 Cr
News | May 12, 2025

Aarti Drugs Ltd Q4 FY2025 consolidated PAT climbs to Rs. 62.86 Cr

The company has posted net profit of Rs.168.16 crores for the Financial Year ended March 31, 2025


Lupin launches Eslicarbazepine Acetate tablets in US
Drug Approval | May 08, 2025

Lupin launches Eslicarbazepine Acetate tablets in US

Lupin is one of the first ANDA applicants and is eligible for 180 days of shared generic exclusivity


Alembic Pharmaceuticals posts Q4 FY25 consolidated PAT at Rs. 156.63 Cr
News | May 06, 2025

Alembic Pharmaceuticals posts Q4 FY25 consolidated PAT at Rs. 156.63 Cr

The company has posted net profit of Rs. 582.01 crores for the Financial Year ended March 31, 2025


OneSource Specialty Pharma reports consolidated Q4 FY25 PAT at Rs. 98.50 Cr
News | May 06, 2025

OneSource Specialty Pharma reports consolidated Q4 FY25 PAT at Rs. 98.50 Cr

The company has posted net loss of Rs. 17.97 crores for the Financial Year ended March 31, 2025


Ami Organics Q4 FY25 PAT up at Rs. 62.48 Cr
News | May 05, 2025

Ami Organics Q4 FY25 PAT up at Rs. 62.48 Cr

The company has posted net profit of Rs. 158.71 crores for the Financial Year ended March 31, 2025